Exonate Ltd, a spin-out of the University of Nottingham, has raised further money from the venture capital community to support its candidate eye drop for treating retinal neovascular diseases. The latest round raised £1.5 million for a total to date of £9 million.
The UK company is supported by Uniseed of Australia, the University of Bristol Enterprise Fund, Angel CoFund and a number of other investors.